TY  -  
T1  - Randomized Trial of Peginterferon alfa-2b and Ribavirin for 48 or 72 Weeks in Patients with Hepatitis C Virus Genotype 1 and Slow Virologic Response 
SN  -  /  
UR  - http://hdl.handle.net/10138/252447 
T3  -  
A1  - SUCCESS Study Investigators; Färkkilä, Martti 
A2  -  
PB  -  
Y1  - 2010 
LA  - eng 
AB  - The benefit of extending treatment duration with peginterferon (PEG-IFN) and ribavirin (RI3V) from 48 weeks to 72 weeks for patients with chronic hepatitis C genotype 1 infection has not been well established. In this prospective, international, open-label, randomized, multicenter study, 1,428 treatment-nave patients from 133 centers were treated with PEG-IFN alfa-26 (1.5 mu g/kg/week) plus RBV (800-1,400 mg/day). Patients with detectable hepatii is C virus (HCV) RNA and a >= 2-logio drop in IIC... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - PLUS RIBAVIRIN; TREATMENT DURATION; COMBINATION THERAPY; INFECTION; 3121 General medicine, internal medicine and other clinical medicine 
N1  -   
PP  -  
ER  -